跳至主要内容
临床试验/NCT03831802
NCT03831802终止不适用

Quality of Life in Epilepsy Patients Wearing a Biosensor for Seizure Detection Through Electrodermal Activity and Accelerometry - a Pilot Study

Centre Hospitalier Universitaire Vaudois2 个研究点 分布在 1 个国家目标入组 26 人开始时间: 2018年10月10日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
26
试验地点
2
主要终点
The mean change from Baseline of the total score, of the french version of the Quality of life Epilepsy inventory-31

研究概览

简要总结

A prospective, open, randomized, pilot clinical trial which aims the assessment of quality of life (QOL) in epilepsy outpatients equipped with a wrist-worn biosensor that provides measures of electrodermal activity and accelerometry. These measures are used to automatically detect epileptic seizures that are transmitted to a mobile phone-based system for alerts and recording.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • male or female aged >18 years old
  • clearcut diagnosis of epilepsy without evidence of non epileptic psychogenic seizure
  • primary tonic clonic seizures or focal seizures evolving to generalized tonic clonic convulsion
  • seizure frequency > 1 seizure/month during the last three months
  • signed the informed consent form
  • own a mobile phone device compatible with the embrace apps
  • able to use the device without help from caregivers

排除标准

  • patients aged less than 18 years old
  • epilepsy diagnosis remains uncertain
  • evidence of psychogenic non epileptic seizures
  • seizure frequency below 1/month during any of the three previous months
  • past-history of nickel allergy and contact dermatitis
  • did not sign the informed consent form
  • does not own mobile phone device compatible with the embrace apps
  • cognitive or behavioral impairment preventing compliance or correct use of the device and app.

结局指标

主要结局

The mean change from Baseline of the total score, of the french version of the Quality of life Epilepsy inventory-31

时间窗: 3 month

The change between the QOLIE-31 questionnaire total score measured at the first and the final visit will serve as primary endpoint. The possible range of each scale's final score is from 0 to 100. higher scores reflect better quality of life.

次要结局

  • The mean change from Baseline of the total scores of seven Quality of Life in Epilepsy Inventory-31 subscales covering the following epilepsy-specific domains:(3 month)
  • Total number of true and false positives seizure detection(3 month)
  • The usability total score of Embrace and Mate apps(3 month)
  • The utility total score of the system in general(3 month)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Philippe Ryvlin

Head of Department of Clinical Neurosciences

Centre Hospitalier Universitaire Vaudois

研究点 (2)

Loading locations...

相似试验